{"name":"S-Evans Biosciences Co., Ltd.","slug":"s-evans-biosciences-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"exogenous indulin injection daily","genericName":"exogenous indulin injection daily","slug":"exogenous-indulin-injection-daily","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"exogenous indulin injection daily","genericName":"exogenous indulin injection daily","slug":"exogenous-indulin-injection-daily","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxOVEhlV3lXbWJaOVROcEtVQnhhNk1RZHd0OXFSR09mMjBuZFktcVg0SkZ5U1pZUWVjcGpmNG5qb0c2YTgtd19lRVZmN1JBazF2NWE3Nm5Jc1Rpd0R6LVJBbHpYQ01va1dNNXlaNVJZdHhXb2FiZy1vZF82R01CR0p6RUM1djBBejBQTzJr?oc=5","date":"2025-02-12","type":"pipeline","source":"statnews.com","summary":"Tome founders launch next venture, an RNA contract research startup - statnews.com","headline":"Tome founders launch next venture, an RNA contract research startup","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4gFBVV95cUxQdnVZVXF6N3Z5eDExaE9KVFh1OHJ2TTZ5X1JvOHJ1MTRvTTV5eGlwRUpleG95V2Q0a1RWX3Y4bWtNbGpGM3NfMUY5Ykh1MjI2eXpfS2ppNGstREF0OVFZVDctVFB1dEdTTlhqV3dLVjFiTW1aX2JCSGVwMlAxUjIxSFNTZFhLX054dlo5SWxZYWp0bXJTN1RhWnZjTHBRQVlwWlh6UDVkZFFCeUR5R1BxTHRiSEg4ekN1SE1rdUo4dDd3LXRoZFpvUjhsWU02WG9naE9jZDhIbnhISWFVLTJCWFJ3?oc=5","date":"2021-04-06","type":"pipeline","source":"Business Wire","summary":"David Evans Shaw Invests in Maxwell Biosciences to Advance the New Class of Antiviral Drugs - Business Wire","headline":"David Evans Shaw Invests in Maxwell Biosciences to Advance the New Class of Antiviral Drugs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxQVEdWY19ONURpSzFuSU80eUZQWWYyMjViZ2VGZDgzUGVtSUFqRnJHaFdJT1NyQ1E1Q2Q3ZTJ1ejB5YS1FSFFkMDJaR0pBZXpWSFpkdkphOHVpUzE4MTRMMkRLWXk4LXdKZE1va0JYejRBaWFlWUNsMmNvSXYycXdlaE1sUWRlZVljV3ZhcHBJeWQ5QUNlVVow0gGcAUFVX3lxTE1IbWxwWDJSTU96UHFyU3NXYmtza3hTUVJBanVnZV83Vk9mWHBOU2Z2UnZDY1B6S0p1b1l2WnFOV3RUcXlteTdqZmFCMGVwWEgydTFrN2lIWnYxdVNtQ1B6dHVNalVhQTFrbjVEa1FJZ1ZZNWx2dTQ0QS1oU2JmcUcxQzNnbjJzYk5ac2RwNkRENjVMVVItZEl6OHJ2cg?oc=5","date":"2015-09-11","type":"trial","source":"BioInformant","summary":"Breakdown of Mesenchymal Stem Cell Clinical Trials, by Phase, Geography, Sponsors, and More - BioInformant","headline":"Breakdown of Mesenchymal Stem Cell Clinical Trials, by Phase, Geography, Sponsors, and More","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}